These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25380723)

  • 1. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.
    Hock MB; Thudium KE; Carrasco-Triguero M; Schwabe NF
    AAPS J; 2015 Jan; 17(1):35-43. PubMed ID: 25380723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.
    Kaur S; Xu K; Saad OM; Dere RC; Carrasco-Triguero M
    Bioanalysis; 2013 Jan; 5(2):201-26. PubMed ID: 23330562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.
    Sauerborn M; van Dongen W
    BioDrugs; 2014 Aug; 28(4):383-91. PubMed ID: 24842227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates.
    Hoofring SA; Lopez R; Hock MB; Kaliyaperumal A; Patel SK; Swanson SJ; Chirmule N; Starcevic M
    Bioanalysis; 2013 May; 5(9):1041-55. PubMed ID: 23641695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of a Plug-and-Play Immunogenicity Assay in Cynomolgus Monkey Serum for ADCs at Early Stages of Drug Development.
    Carrasco-Triguero M; Davis H; Zhu Y; Coleman D; Nazzal D; Vu P; Kaur S
    J Immunol Res; 2016; 2016():2618575. PubMed ID: 27092313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conference report: hot topics in antibody-drug conjugate development.
    Thudium K; Bilic S
    Bioanalysis; 2013 Dec; 5(24):2989-93. PubMed ID: 24320125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper.
    Gorovits B; Alley SC; Bilic S; Booth B; Kaur S; Oldfield P; Purushothama S; Rao C; Shord S; Siguenza P
    Bioanalysis; 2013 May; 5(9):997-1006. PubMed ID: 23641692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.
    Stephan JP; Kozak KR; Wong WL
    Bioanalysis; 2011 Mar; 3(6):677-700. PubMed ID: 21417735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study.
    Myler H; Rangan VS; Wang J; Kozhich A; Cummings JA; Neely R; Dail D; Liu A; Wang B; Vezina HE; Freebern W; Sung MC; Passmore D; Deshpande S; Kempe T; Gu H; Saewert M; Manney A; Lute J; Zambito F; Wong RL; Piccoli SP; Aubry AF; Pillutla R; Arnold M; DeSilva B
    Bioanalysis; 2015; 7(13):1569-82. PubMed ID: 26226308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays.
    Kumar S; King LE; Clark TH; Gorovits B
    Bioanalysis; 2015; 7(13):1605-17. PubMed ID: 26226310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials.
    Carrasco-Triguero M; Dere RC; Milojic-Blair M; Saad OM; Nazzal D; Hong K; Kaur S
    Bioanalysis; 2019 Sep; 11(17):1555-1568. PubMed ID: 31208199
    [No Abstract]   [Full Text] [Related]  

  • 13. Coming-of-Age of Antibodies in Cancer Therapeutics.
    Ayyar BV; Arora S; O'Kennedy R
    Trends Pharmacol Sci; 2016 Dec; 37(12):1009-1028. PubMed ID: 27745709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on the draft ICH-M10 guidance: an interview with Boris Gorovits.
    Gorovits B
    Bioanalysis; 2019 Aug; 11(15):1383-1385. PubMed ID: 31490105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.
    Dere R; Yi JH; Lei C; Saad OM; Huang C; Li Y; Baudys J; Kaur S
    Bioanalysis; 2013 May; 5(9):1025-40. PubMed ID: 23641694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates.
    Lansita JA; Burke JM; Apgar JF; Mounho-Zamora B
    Pharm Res; 2015 Nov; 32(11):3584-92. PubMed ID: 26108879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates.
    Saad OM; Shen BQ; Xu K; Khojasteh SC; Girish S; Kaur S
    Bioanalysis; 2015; 7(13):1583-604. PubMed ID: 26226309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unwanted immunogenicity: lessons learned and future challenges.
    Wadhwa M; Thorpe R
    Bioanalysis; 2010 Jun; 2(6):1073-84. PubMed ID: 21083209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.
    McCombs JR; Owen SC
    AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights on the immunogenicity of antibody-drug conjugates.
    Carrasco-Triguero M
    Bioanalysis; 2015; 7(13):1565-8. PubMed ID: 26226307
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.